RMD ResMed Inc.

ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health

ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health

  • ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir consumer app with Apple and Android smartwatches.
  • Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling.

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced new patient-centric products designed to enhance the therapy journey for sleep apnea patients. integrate with digital wearable devices and generative artificial intelligence designed to deliver a more personalized sleep health experience and improve overall health.

ResMed’s found that 44% of Americans get fewer than three good nights of sleep each week, significantly impacting their quality of life. With the rising popularity of digital wearables like smartwatches and health trackers, individuals now have access to data-driven insights that empower them to be active participants in improving their health. Sleep health has become a key focus in this evolving landscape, with more than half (54%) of respondents from a recent ResMed expressing interest in purchasing a wearable device with sleep-tracking capabilities.

Digital wearables give consumers instant access to sleep and other critical health insights, giving them valuable information to collaborate with their healthcare providers. ResMed’s latest innovations are designed with users at the forefront, offering personalized insights into sleep patterns and the flexibility to help people stay on track with sleep therapy, no matter where life takes them.

New Patient Engagement Features for ResMed myAir App Designed to Help People Take Control of their Health

ResMed myAir is an intuitive app that empowers patients to stay engaged with their CPAP therapy, leading to better health outcomes. Through interactive coaching and the ability to track nightly sleep data, myAir has been associated with significantly increased CPAP usage, with 87% of patients achieving therapy compliance1.

New myAir Patient Engagement Features Include:

  • myAir smartwatch app: Now available on Apple and Android smartwatches, this app allows users to monitor their therapy data at a glance, making it easier to stay engaged with CPAP therapy.
  • Sleep staging: Integrates sleep stages data (awake, REM, core, and deep) from Apple Health and Health Connect into myAir, giving users a clearer understanding of their entire sleep cycle.
  • Personalized coaching: Offers customized tips and strategies based on behavior science and machine learning to help users stay on track with CPAP therapy through personalized support.
  • Holistic trends: Provides a comprehensive view of a user’s health by providing data such as tracked steps, energy burned, weight, blood oxygen, body mass index, daily exercise, heart rate variability, resting heart rate, time in bed, and total time asleep, from Apple Health and Health Connect along with CPAP therapy data, all in one place.

“We know that digital wearables and other innovative technologies like AI can help consumers better understand their sleep habits and create a personalized pathway to better rest,” said Carlos M. Nunez, M.D., Chief Medical Officer at ResMed. “Regular sleep tracking can offer crucial insights that empower people to make informed decisions about improving their sleep quality both now and in the future.”

Introducing Dawn: A Generative AI-Enabled Sleep Health Concierge

ResMed’s new AI-enabled health concierge, Dawn, is changing how people learn about sleep apnea. Dawn provides instant, 24/7 access to many answers about sleep health, ResMed products, and CPAP therapy support. Using Generative AI, Dawn offers personalized guidance and connects users with the information they need in real time.

LUXE, Thoughtfully Designed Travel Gear for CPAP Users

Catering to frequent travelers with an eye for sophisticated design, ResMed introduces the LUXE range of tote bags and backpacks. The stylish, practical travel bags are engineered to make it easier for people to stay on CPAP therapy while on the move. LUXE includes modular inserts to securely carry the AirSense™ 10/11 or AirMini™, a mask, a tube, and a power supply. Available for purchase in limited quantities via (US), (AU), and the Tmall platform (China) on October 28.

For more information on ResMed’s latest suite of innovations and new products, please visit .

Android is a trademark of Google LLC. Apple® is a registered trademark of Apple, Inc.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we help improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit  and follow @ResMed.

For Media: 

Rebecca Ehlinger-Janzon

(760) 496-8320

TEAM LEWIS

For Investors:

+1 858.836.5000


1 Malhotra A et al. Patient engagement using new technology to improve adherence to positive airway pressure therapy: A retrospective analysis. Chest. 2018;153:843–850. doi: 10.1016/j.chest.2017.11.005.

Photos accompanying this announcement are available at:



EN
30/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

ResMed Inc: 2 directors

Two Directors at ResMed Inc sold 2,050 shares at between 251.310USD and 260.000USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

 PRESS RELEASE

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 20...

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today an...

 PRESS RELEASE

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 20...

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST /...

 PRESS RELEASE

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthca...

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay...

 PRESS RELEASE

Resmed Receives FDA Clearance for Personalized Therapy Comfort Setting...

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapy  SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Setting...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch